Felip Enriqueta, Santarpia Mariacarmela, Rosell Rafael
Institut Català d'Oncologia, Hospital Germans Trias I Pujol, Ctra. Canyet. s/n, 08916 Badalona, Barcelona, Spain.
Expert Opin Emerg Drugs. 2007 Sep;12(3):449-60. doi: 10.1517/14728214.12.3.449.
Non-small-cell lung cancer (NSCLC) accounts for 80% of all lung cancer cases and is the leading cause of cancer mortality. Despite the optimization of chemotherapy regimens, treatment outcomes for advanced disease are still disappointing. The EGFR tyrosine kinase inhibitor, erlotinib, and the recombinant monoclonal antibody against the VEGF, bevacizumab, have proven active in NSCLC. In the BR.21 trial, a 2-month benefit in overall survival was observed for previously treated NSCLC patients who received erlotinib versus placebo. The combination of chemotherapy plus bevacizumab yielded superior overall survival or progression-free survival in one randomized trial in advanced non-squamous NSCLC patients. However, despite the introduction of more effective agents, new treatment strategies are clearly needed in lung cancer management. The review focuses on a number of new targeted agents/chemotherapy drugs now in clinical trials directed at improving NSCLC management. Mature results regarding their activity and usefulness can be expected in the near future.
非小细胞肺癌（NSCLC）占所有肺癌病例的80%，是癌症死亡的主要原因。尽管化疗方案已得到优化，但晚期疾病的治疗效果仍然令人失望。表皮生长因子受体（EGFR）酪氨酸激酶抑制剂厄洛替尼和抗血管内皮生长因子（VEGF）的重组单克隆抗体贝伐单抗已被证明在NSCLC中具有活性。在BR.21试验中，接受厄洛替尼治疗的既往治疗过的NSCLC患者与接受安慰剂治疗的患者相比，总生存期延长了2个月。在一项针对晚期非鳞状NSCLC患者的随机试验中，化疗联合贝伐单抗可提高总生存期或无进展生存期。然而，尽管引入了更有效的药物，但肺癌治疗显然仍需要新的治疗策略。本综述重点关注了目前正在进行临床试验的一些新型靶向药物/化疗药物，旨在改善NSCLC的治疗。预计在不久的将来可以获得有关其活性和效用的成熟结果。
